Hayflick Partners is a development stage company that is leveraging new scientific discoveries in aging biology to address specific health and aesthetic concerns associated with declining cellular function. Our research team includes experts in the study of rapamycin and its efficacy across a variety of clinical settings. Our flagship investigational product is a low-dose topical therapeutic agent that is designed to deliver the healthspan benefits of rapamycin while minimizing systemic exposure.